EBS — Emergent BioSolutions Inc. stock price, charts and financials

Latest market price

7.57

+0.16+2.16%

Overview Short InterestFilings

EBSQT48Emergent BioSolutions Inc.·NYSE

Overview Short InterestFilings

7.57+2.16%

Earnings

Up 2.2% — Reported earnings — EPS beat by 184%, revenue beat by 8%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	17.37%	Shs Outstand	51.60M	Perf Week	3.56%

Market Cap	390.58M	Forward P/E	8.32	EPS next Y	0.91	Insider Trans	-0.77%	Shs Float	48.72M	Perf Month	-7.46%

Enterprise Value	804.58M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	21.22%	Perf Quarter	-11.36%

Income	-9.00M	P/S	0.58	EPS this Y	216.07%	Inst Trans	-	Short Ratio	12.57	Perf Half Y	-35.35%

Sales	677.00M	P/B	0.75	EPS next Y	180.00%	ROA	-0.65%	Short Interest	10.34M	Perf YTD	-38.75%

Book/sh	10.14	P/C	2.44	EPS next 5Y	40.43%	ROE	-1.59%	52W High	14.06 -46.16%	Perf Year	34.46%

Cash/sh	3.10	P/FCF	2.75	EPS past 3/5Y	- -30.34%	ROIC	-14.93%	52W Low	5.62 34.70%	Perf 3Y	11.65%

Dividend Est.	-	EV/EBITDA	5.16	Sales past 3/5Y	-12.73% -13.97%	Gross Margin	44.44%	Volatility	3.56% 3.55%	Perf 5Y	-87.93%

Dividend TTM	-	EV/Sales	1.19	EPS Y/Y TTM	92.22%	Oper. Margin	10.52%	ATR (14)	0.30	Perf 10Y	-77.23%

Dividend Ex-Date	-	Quick Ratio	2.08	Sales Y/Y TTM	-35.15%	Profit Margin	-1.27%	RSI (14)	46.74	Recom	2.33

Dividend Gr. 3/5Y	-	Current Ratio	4.29	EPS Q/Q	-70.42%	SMA20	-0.54%	Beta	2.36	Target Price	12.00

Payout	0.00%	Debt/Eq	1.09	Sales Q/Q	-29.73%	SMA50	-5.84%	Rel Volume	0.60	Prev Close	7.41

Employees	900	LT Debt/Eq	1.09	Earnings	Aug 05	SMA200	-21.06%	Avg Volume	810.08K	Price	7.57

IPO Date	Nov 15, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	184.00% 7.66%	Net Debt/EBITDA	2.68	Volume	488,905	Change	2.16%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-09-26	Reiterated	HC Wainwright & Co.	Buy	$12
Mar-07-24	Upgrade	Benchmark	Hold → Buy
Aug-29-23	Downgrade	Benchmark	Buy → Hold
Apr-10-23	Upgrade	Benchmark	Hold → Buy
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-10-22	Downgrade	Benchmark	Buy → Hold
May-04-22	Reiterated	Wells Fargo	Equal Weight
Apr-29-22	Reiterated	Chardan Capital	Buy
Nov-08-21	Downgrade	Benchmark	Buy → Hold
May-05-21	Downgrade	Argus Research	Buy → Hold

Latest News

Jul-22-26

Jul-22-2604:01PM

Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026globenewswire.com

Jul-01-26

Jul-01-2612:19PM

'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg NewsBenzinga

Jun-29-26

Jun-29-2609:13AM

Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Governmentglobenewswire.com

Jun-26-26

Jun-26-2601:10PM

CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains LowBenzinga

Jun-16-26

Jun-16-2608:50AM

FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga

Company

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	677	743	1,044	1,049	1,118	1,774	1,577	1,106	782
Cost of Goods Sold Incl. D&A	376	392	668	689	645	980	714	623	462
Gross Profit	302	351	375	360	473	793	863	483	320
Selling, General and Administrative Excl. Other	181	187	299	357	340	349	304	274	203
Research and Development	50	54	71	111	188	235	238	226	143
Other Operating Expense	-2	-1	114	618	115	-132	-117	-131	-115
Operating Income	72	110	-109	-726	-170	341	439	114	90
Interest Expense	56	59	71	88	37	35	31	38	10
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-12	32	37	83	-12	-4	5	2	2
Net Income Before Taxes	3	83	-143	-731	-219	303	412	77	82
Income Taxes	12	30	48	29	-7	84	106	23	19
Consolidated Net Income	-9	53	-191	-760	-212	220	306	55	63
Net Income From Continuing Operations	-9	53	-191	-760	-212	220	306	55	63
Net Income	-9	53	-191	-760	-212	220	306	55	63
EPS (Recurring)	-0.17	0.98	-3.60	-14.85	-4.22	4.10	5.79	1.06	1.25
EPS (Basic, Before Extraordinaries)	-0.17	0.98	-3.60	-14.85	-4.22	4.10	5.79	1.06	1.25
EPS (Diluted)	-0.28	0.93	-3.60	-14.85	-4.22	4.06	5.67	1.04	1.22
EBITDA	156	240	53	-47	16	504	609	259	155
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	13.29	—	—	—	10.71	15.80	51.88	48.59
Price To Sales Ratio	0.58	0.90	0.49	0.12	0.53	1.32	3.01	2.54	3.79
Gross Margin	44.61	47.24	35.92	34.32	42.31	44.70	54.72	43.67	40.92
Operating Margin	10.64	14.80	-10.44	-69.21	-15.21	19.22	27.84	10.31	11.51
Net Margin	-1.33	7.13	-18.30	-72.45	-18.96	12.40	19.40	4.97	8.06
Shares Outstanding	52	54	53	51	50	54	53	52	50
Market Capitalization	394	667	507	122	591	2,347	4,749	2,805	2,964
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Paul Anthony	SVP, Products Business	Jul 01 '26	Sale	8.40	3,000	25,200	159,098	Jul 02
DeGolyer Donald W	Director	May 01 '26	Sale	8.40	15,481	129,994	129,721	May 04
Dayal Sujata Tyagi	Director	May 01 '26	Sale	8.40	13,761	115,610	100,563	May 04
Zoon Kathryn C	Director	May 01 '26	Sale	8.40	17,202	144,453	79,941	May 04
Katkin Keith	Director	Apr 30 '26	Sale	8.28	15,481	128,183	96,294	May 04
Williams Paul Anthony	SVP, Products Business	Apr 01 '26	Sale	8.44	4,000	33,760	62,681	Apr 03
Richard Ronald	Director	Dec 05 '25	Option Exercise	5.02	25,748	129,255	124,165	Dec 09
Richard Ronald	Director	Dec 05 '25	Sale	11.97	21,984	263,077	98,417	Dec 09
DeGolyer Donald W	Director	Nov 10 '25	Sale	10.54	17,801	187,623	119,858	Nov 12
Dayal Sujata Tyagi	Director	Nov 07 '25	Sale	10.00	8,552	85,520	88,980	Nov 10
Glessner Coleen	EVP, Quality & Ethics, and CPL	Oct 07 '25	Sale	10.00	30,608	306,080	144,319	Oct 16
Zoon Kathryn C	Director	Aug 15 '25	Sale	8.87	7,086	62,853	71,799	Aug 18
DeGolyer Donald W	Director	Aug 12 '25	Sale	8.65	7,844	67,831	137,659	Aug 13
Katkin Keith	Director	May 23 '25	Sale	6.30	7,844	49,417	86,431	May 28
PAPA JOSEPH C	President and CEO	May 13 '25	Buy	5.83	60,000	349,800	342,500	May 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.